Benzinga | Jan 21, 2022 07:02AM EST

B of A Securities Downgrades CureVac to Underperform, Lowers Price Target to $20

B of A Securities analyst Geoff Meacham downgrades CureVac (NASDAQ:CVAC) from Neutral to Underperform and lowers the price target from $55 to $20.